Rocío Gallego‐Durán
A5063440729- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Diet, Metabolism, and Disease
- Alcohol Consumption and Health Effects
- Endoplasmic Reticulum Stress and Disease
- Hepatitis C virus research
- Diet and metabolism studies
- Lipid metabolism and disorders
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Pancreatitis Pathology and Treatment
- Cardiovascular Disease and Adiposity
- Pancreatic function and diabetes
- Cancer, Hypoxia, and Metabolism
- Metabolism and Genetic Disorders
- Peroxisome Proliferator-Activated Receptors
- Pharmacology and Obesity Treatment
- Cholesterol and Lipid Metabolism
- Health and Lifestyle Studies
- Adipose Tissue and Metabolism
- Nutritional Studies and Diet
- Diabetes and associated disorders
- Cerebrospinal fluid and hydrocephalus
Instituto de Biomedicina de Sevilla
2016-2025
Hospital Universitario Virgen del Rocío
2016-2025
Universidad de Sevilla
2016-2025
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016-2025
Hospital Clínico Universitario de Valencia
2024
Andalusian Health Service
2024
Centre for Biomedical Network Research on Rare Diseases
2022-2024
Instituto de Salud Carlos III
2016-2023
Hospital General Universitario Gregorio Marañón
2023
Consejo Superior de Investigaciones Científicas
2021-2022
Objective The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis Caucasian with NAFLD. Design study cohort comprises 1339 biopsy-proven NAFLD from four countries (Italy, UK, Spain Australia), stratified into non-lean (body mass index (BMI) </≥25 kg/m 2 ). Liver/non-liver-related events survival free transplantation were recorded during the...
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most common chronic worldwide. It important to develop noninvasive tests assess severity and prognosis.
Objective Hyperferritinaemia is associated with liver fibrosis severity in patients metabolic dysfunction-associated steatotic disease (MASLD), but the longitudinal implications have not been thoroughly investigated. We assessed role of serum ferritin predicting long-term outcomes or death. Design evaluated relationship between baseline and events a multicentre cohort 1342 patients. Four survival models considering confounders non-invasive scoring systems were applied repeated five-fold...
Background Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). Aim To explore the effects of statins on long-term risk all-cause mortality, liver-related clinical events (LREs) and stiffness progression MASLD. Methods This cohort study collected data MASLD undergoing at least two vibration-controlled transient elastography examinations 16 tertiary referral centres. Cox regression analysis was performed to examine association between statin...
Current guidelines recommend a 2-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Fibrosis-4 index (FIB-4) followed by stiffness measurement (LSM) vibration-controlled transient elastography (VCTE) or similar second-line tests. This study aimed to examine prognostic performance of this approach. The VCTE-Prognosis Study was longitudinal MASLD who had undergone VCTE examinations at 16 centres from the US, Europe and Asia...
Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, polymorphism in the MBOAT7 locus, as being associated with development alcoholic cirrhosis. Here we explore role this variant on inflammation and fibrosis two cohorts patients chronic hepatitis C. In 2,051 patients, rs641738 severe hepatic increased risk fibrosis, well fast progression. At functional level, transcript protein levels blood, serum...
Summary Background Metabolically healthy obesity ( MHO ) shows a reduced risk compared with obese patients adverse metabolic conditions. Lean people suffering some derangements also have non‐alcoholic fatty liver disease NAFLD )‐related outcomes non‐obese subjects few risks. Aim To define the impact of status on ‐related outcomes, beyond presence obesity. Methods We designed multicentre cross‐sectional study, including 1058 biopsy‐proven patients. was strictly defined by lack factors...
•Accumulation of noxious metabolites in the interstitial fluid brain may contribute to hepatic encephalopathy.•Accumulation such products be due reduced glymphatic clearance mechanisms brain.•We identified regions impaired function, which aligned closely with cognitive/behavioural deficits.•Reduced AQP4 expression was observed same regions.•Altered mediated dysfunction pathogenesis encephalopathy. Background & AimsNeuronal function is exquisitely sensitive alterations extracellular...
The main aim was to evaluate changes in urea cycle enzymes NAFLD patients and two preclinical animal models mimicking this entity. Seventeen liver specimens from were included for immunohistochemistry gene expression analyses. Three-hundred-and-eighty-two biopsy-proven genotyped rs1047891, a functional variant located carbamoyl phosphate synthetase-1 (CPS1) gene. Two employed analyse CPS1 by immunohistochemistry, choline deficient high-fat diet model (CDA-HFD) high fat LDLr knockout (LDLr...
We aimed to assess the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) at a multi-scale level.
Scope We evaluated the protective effect of extra virgin olive oil (EVOO) in high‐fat diets (HFDs) on inflammatory response and liver damage a nonalcoholic fatty disease (NAFLD) mouse model. Methods results C57BL/6J mice were fed standard diet or lard‐based HFD (HFD‐L) for 12 wk to develop NAFLD. HFD‐fed then divided into four groups 24 with following: HFD‐L, HFD‐EVOO, based phenolics‐rich EVOO, reversion (standard diet). HFD‐L‐induced metabolic disorders alleviated by replacement lard EVOO....
Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed profile miRNAs comprehensively at all NAFLD stages.
Abstract Background and Aims Liver cancer stem cells (CSCs) could be involved in the carcinogenesis, recurrence, metastasis chemoresistance of hepatocellular carcinoma (HCC). The aim this study was to explore role lncRNA‐ H19 as a biomarker for liver cancer. Methods LncRNA‐ expression levels functional assays were conducted EpCAM + CD133 CSCs C57BL/6J mice fed with high‐fat high‐cholesterol carbohydrate (HFHCC) or standard diet 52 weeks. tissue plasma samples from patients cirrhosis, without...
Abstract Background Soluble CD 36 ( sCD 36) clusters with insulin resistance, but no evidence exists on its relationship hepatic fat content. We determined to assess link steatosis in nonalcoholic fatty liver disease NAFLD ) and chronic hepatitis C CHC patients. Materials methods Two hundred twenty‐seven , eighty‐seven eighty‐five patients histologically normal NL were studied. Steatosis was graded by K leiner's histological scoring system. Serum expression assessed immunoassay...
Non-alcoholic fatty liver disease (NAFLD) is an emerging health concern in both developed and non-developed world, encompassing from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis cancer.Incidence prevalence of this are increasing due the socioeconomic transition change harmful diet.Currently, gold standard method NAFLD diagnosis biopsy, despite complications lack accuracy sampling error.Further, pathogenesis not fully understood, but well-known that obesity, diabetes...